Mylan Laboratories Limited, (Nashik FDF) FDA Warning (2017)
Compiled by the Supplement Safety Data Team | Sourced from Official FDA Records on April 03, 2017
Executive Summary
The FDA issued a warning letter to Mylan Laboratories Limited, (Nashik FDF) on April 03, 2017 citing cgmp violations. The letter was issued by Center for Drug Evaluation and Research.
Detailed Analysis
False Claims and Regulatory Violations
The FDA identified regulatory violations in Mylan Laboratories Limited, (Nashik FDF)'s operations or product claims.
Potential Health Risks
Consumers should be aware of potential risks associated with products from Mylan Laboratories Limited, (Nashik FDF).
Regulatory Context
shown exactly how widespread these problems are;
or demonstrated how you will ensure that your quality unit reviews, investigates, and acts upon codes that affect the reliability of your CGMP data.
Key Entities Identified
Frequently Asked Questions
- What did the FDA find wrong with Mylan Laboratories Limited, (Nashik FDF)?
- The FDA issued a warning letter citing cgmp violations related to their products or manufacturing practices.
- Are Mylan Laboratories Limited, (Nashik FDF) products safe to use?
- Based on the FDA's findings, consumers should exercise caution. The company was found to have cgmp violations that may affect product safety.
- What should I do if I've used Mylan Laboratories Limited, (Nashik FDF) products?
- If you have used products from Mylan Laboratories Limited, (Nashik FDF) and experience any adverse effects, contact your healthcare provider immediately. You can also report adverse events to the FDA's MedWatch program.
Source Document
This report is based on an official FDA warning letter. The original document is a public record.
View Original FDA Warning Letter